Hematology/Oncology

Top Story

ED interventions reduce time to treatment of febrile neutropenia

August 31, 2015

The implementation of an intervention pathway reduced the time to administration of necessary antibiotics in the emergency department among adult patients with cancer experiencing febrile neutropenia, according to results of a prospective study conducted at Cleveland Clinic.

Febrile neutropenia — a serious complication of chemotherapy — is associated with mortality rates as high as 58% in patients with multiple comorbidities. Most practice guidelines recommend the administration of antibiotics within 1 hour of documented fever.

In the Journals

Readmission rates may skew hospital quality measurements

August 31, 2015
Readmission rates were an ineffective measure of a hospital’s quality because they did not take into account readmissions from different hospitals, resulting in a…
NYU Langone appoints neuro-oncology chief

NYU Langone appoints neuro-oncology chief

August 30, 2015
Andrew S. Chi, MD, PhD, has been appointed chief of neuro-oncology at NYU Langone Medical Center’s Laura and Isaac Perlmutter Cancer Center.Chi, a…
Institution Notes

MD Anderson appoints orthopedic oncology department chair

August 29, 2015
Valerae O. Lewis, MD, has been named chair of the department of orthopedic oncology at The University of Texas MD Anderson Cancer Center.Lewis, whose clinical focus is…
Timothy J. Ley, MD In the Journals

Persistent mutations may predict EFS, OS outcomes in AML

August 28, 2015
Persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples appeared to significantly increase the risk for relapse and…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »